BCDA

CAS No. 3252-36-6

BCDA( 5-bromo-4-chloroindoxyl acetate )

Catalog No. M24259 CAS No. 3252-36-6

BCDA is a chromogenic substrate of esterase. It is used to detect the activity of esterase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 29 In Stock
25MG 40 In Stock
50MG 57 In Stock
100MG 83 In Stock
200MG Get Quote In Stock
500MG 221 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BCDA
  • Note
    Research use only, not for human use.
  • Brief Description
    BCDA is a chromogenic substrate of esterase. It is used to detect the activity of esterase.
  • Description
    BCDA is a chromogenic substrate of esterase. It is used to detect the activity of esterase.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    5-bromo-4-chloroindoxyl acetate
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3252-36-6
  • Formula Weight
    288.52
  • Molecular Formula
    C10H7BrClNO2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol:100 mg/mL (346.58 mM)
  • SMILES
    CC(Oc1c[nH]c(cc2)c1c(Cl)c2Br)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Thalidomide-O-amido-...

    Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

  • α-Casein 90-95

    α-Casein (90-95) is a peptide fragment of α-Casein.

  • MID-1

    MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction.?It disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake.